Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Delin Ventures is a mission-driven investment organization founded to support entrepreneurs and scientists in life sciences and technology. Established in London and Cambridge, the firm focuses on building and investing in companies that leverage breakthrough technologies to improve human lives. Delin Ventures operates with a 'patient capital' philosophy, prioritizing long-term impact and scientific success over short-term financial returns.
The firm manages two primary funds: the Life Sciences Fund and the Technology Fund. The Life Sciences Fund invests in cell therapy companies from pre-seed onwards, while the Technology Fund targets pre-seed and seed stage investments in innovative tech across Germany, Austria, and Switzerland. Delin Ventures emphasizes operational expertise and a strong network to support portfolio companies, enhancing their chances of success.
As of now, Delin Ventures has a total AUM of $58 million and has invested in 10 companies across various sectors. The firm is committed to being a leading investor in promising cell therapies and their enabling infrastructure, reflecting its focus on impactful advancements in human health and technology.
Delin Ventures operates with a clear investment strategy that encompasses two distinct funds: the Life Sciences Fund and the Technology Fund. The Life Sciences Fund is dedicated to investing in and building scalable cell therapy companies from pre-seed onwards. This fund emphasizes therapeutics, services, and manufacturing technologies, aiming to support innovations that can significantly impact human health.
The Technology Fund, on the other hand, targets pre-seed and seed stage investments in Germany, Austria, and Switzerland, with a check size range of €0.5-2 million. This fund focuses on innovative technology companies, particularly those utilizing AI-enabled operator models. Delin Ventures seeks to partner with founders who demonstrate a strong vision and the capability to execute their ideas effectively.
Delin Ventures is particularly interested in early-stage investments across sectors such as biotech, healthcare, AI, SaaS, and fintech. The firm looks for companies that not only have innovative solutions but also align with their mission of creating long-term value and impact in their respective fields.
Delin Ventures has a diverse portfolio that includes notable companies across the life sciences and technology sectors. The following companies are part of their investment portfolio:
This portfolio reflects Delin Ventures' commitment to supporting innovative solutions in both life sciences and technology, with a focus on companies that have the potential for significant impact.
Igor Linshits: Founder of Delin Ventures, Igor has a background in venture capital and a strong focus on life sciences and technology investments.
Jonathan Hay: Partner at the Life Sciences Fund, Jonathan has extensive experience in biotech investments and has led several successful funding rounds.
Colin Freund: Partner at the Life Sciences Fund, Colin specializes in therapeutics and has a deep understanding of the cell therapy landscape.
Iskender Dirik: Partner at the Technology Fund, Iskender focuses on early-stage technology investments and has a strong track record in scaling tech startups.
Rosie Barnett: Principal at the Life Sciences Fund, Rosie brings expertise in operational support and strategic guidance for portfolio companies.
Alan Barge: Venture Partner at the Life Sciences Fund, Alan has a wealth of experience in the biotech sector and provides valuable insights to portfolio companies.
Matt Symes: Investor at the Life Sciences Fund, Matt focuses on identifying promising investment opportunities in the life sciences space.
Oliver Hemmings: Analyst at the Life Sciences Fund, Oliver supports the investment team with market research and analysis.
Ziaf Rehman: Associate at the Technology Fund, Ziaf assists in evaluating tech investment opportunities and supporting portfolio companies.
Jakub Czarnecki: Financial Controller for both funds, Jakub manages financial operations and reporting.
Muz Mansuri: Advisor at the Life Sciences Fund, Muz provides strategic insights and guidance to portfolio companies.
John Campbell: Entrepreneur-in-Residence at the Life Sciences Fund, John offers mentorship and support to founders.
Larry Illg: Advisor at the Technology Fund, Larry brings extensive experience in tech investments and strategy.
Miguel Forte: Advisor at the Life Sciences Fund, Miguel provides expertise in clinical development and regulatory affairs.
Christopher Spray: Advisor for both funds, Christopher offers insights into market trends and investment strategies.
Sarah Shackelton: Advisor at the Life Sciences Fund, Sarah supports portfolio companies with operational challenges.
To pitch Delin Ventures, founders should use the online application form available at this link. It is essential to include a well-structured pitch deck that outlines the business model, market opportunity, competitive landscape, and the founding team's background.
Delin Ventures appreciates concise and clear presentations that highlight the startup's unique value proposition and potential for impact. Founders should be prepared for follow-up discussions and may need to provide additional information upon request.
Response times can vary, but founders can generally expect to hear back within a few weeks. Warm introductions are beneficial but not mandatory for submission.
In October 2025, Delin Ventures participated in a $100 million Series B funding round for Ori Biotech, a cell and gene therapy manufacturing platform. This investment exemplifies their patient follow-on strategy.
In April 2026, Delin Ventures announced a new fund of £46 million focused on pre-seed and seed investments in Europe, further solidifying their commitment to supporting early-stage companies.
Delin Ventures has also made notable investments in companies like Turbine AI, participating in a $20.5 million Series A round, and Athernal Bio, where they acted as a founding investor with a £3.5 million seed investment.
What are Delin Ventures' investment criteria?
Delin Ventures focuses on early-stage investments in life sciences and technology sectors, specifically targeting pre-seed, seed, seed-plus, and Series A stages. They look for companies that demonstrate innovative solutions in biotech, healthcare, AI, SaaS, and fintech.
How can I pitch to Delin Ventures?
Founders can pitch to Delin Ventures through their online application form available at this link. It is advisable to include a clear business model, market analysis, and the team’s background in the pitch deck.
What makes Delin Ventures different from other investors?
Delin Ventures operates with a 'patient capital' philosophy, prioritizing long-term impact and scientific success over short-term financial returns. They provide not only capital but also strategic support and coaching to help portfolio companies navigate challenges.
What is the geographic focus of Delin Ventures?
The firm primarily invests in companies located in the UK and Europe, particularly in Germany, Austria, and Switzerland for their Technology Fund.
What is the typical check size for investments?
Delin Ventures typically invests between €0.5 million and €2 million in their Technology Fund, while specific check sizes for the Life Sciences Fund may vary based on the stage and needs of the company.
What kind of post-investment involvement does Delin Ventures have?
Delin Ventures is actively involved with their portfolio companies, providing operational support, strategic guidance, and leveraging their network to help startups scale effectively.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.